ClinicalTrials.gg
Active, not recruitingNCT07139327ENTERPRISEUpdated Sep 8, 2026

A Pivotal Study to Evaluate the Efficacy and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults

An interventional study of Cochlear Implant in Hearing Loss, Bilateral Sensorineural, sponsored by Cochlear. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Primary conditionHearing Loss, SensorineuralRegistry: Hearing LossReclassifiedWhy we changed it
Registry
Hearing Loss — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hearing Loss, Sensorineural
Why
  1. The study's title name Hearing Loss, Sensorineural, a narrower term within Hearing Loss.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cochlear · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies in Hearing Loss, Sensorineural by Cochlear — 2 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Sensorineural · Cochlear.

Planned enrollment
12th of 28
36 · median 22
Started
2025
with 3 others
No phase
28 of 32
1 open now
Registered
31st of 32
by date

Among the 32 studies in Hearing Loss, Sensorineural by Cochlear, this one is the 12th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2025, is one of 28 with no phase, and was the 31st registered.

Hearing Loss, Sensorineural

347 studies on the registry are indexed under Hearing Loss, Sensorineural; 102 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

2 of the 32 studies in Hearing Loss, Sensorineural by Cochlear are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Hearing Loss, Sensorineural by Cochlear, or all of them as a file.
02

Study summary

This clinical study examines the performance of an investigational totally implantable cochlear implant (TICI) system. The system includes an implantable microphone under the skin to detect speech and sound from the environment allowing the option to hear without the need of an external sound processor. This implant will be tested in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing and overall general health.

03

Conditions studied

  • Hearing Loss, Bilateral Sensorineural

Browse trials for

Keywords

  • cochlear implant
  • sensorineural hearing loss
04

In context

Hearing Loss, Sensorineural Reclassified

347 studies on the registry are indexed under Hearing Loss, Sensorineural; 102 are open to participants now.

This study's planned enrollment of 36 is above the median of 32 across 248 interventional studies indexed under Hearing Loss, Sensorineural.

Browse Hearing Loss, Sensorineural studies →

Lead sponsor

Cochlear is the lead sponsor of 92 studies on the registry; 9 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Hearing Loss, Sensorineural, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18 years and older at time of consent.
  • Clinically established post-linguistic moderately severe to profound sensorineural hearing loss (PTA4 of >55 dB HL), in the ear to be implanted.
  • Meets local candidacy criteria for cochlear implantation.
  • Compromised functional hearing with a hearing aid in the ear to be implanted, as determined by the investigator.
  • Willing to undergo unilateral cochlear implantation.
  • Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator
  • Direct access to a compatible Smart Phone.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
  • Candidates with single-sided deafness as determined by the investigator.
  • Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
  • Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
  • Cochlear ossification, cochlear malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
  • Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted.
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
  • Preexisting skin condition that could jeopardize wound healing, as determined by the investigator e.g., psoriasis, dermatitis, use of , uncontrolled diabetes.
  • Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation.
  • Women who are pregnant.
  • Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an drug or device.
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    TICI G2 Clinical Investigation System

    Participants will be implanted with the TICI G2 Implant

    Device: Cochlear Implant

Interventions

  • DeviceCochlear Implant

    TICI G2 Clinical Investigation System

07

What researchers measure

Primary outcomes

  1. Speech recognition performance in quiet

    Percent correct word score from preimplantation to post-activation

    Time frame: Preimplantation to 6 months post-activation

  2. Incidence of adverse events and device deficiencies

    Frequency and severity of device and procedure-related adverse events, including device deficiencies

    Time frame: Implantation to 6 and 12 months post-activation

Secondary outcomes

  1. Speech recognition in quiet and noise

    Percent correct scores for word tests in quiet and speech reception threshold scores for sentence tests in noise

    Time frame: Preimplantation to 12 months post-activation

  2. Speech Spatial Qualities questionnaire (SSQ-12)

    Speech, Spatial, and Qualities of Hearing Scale Global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

    Time frame: Preimplantation to 12 months post-activation

  3. Cochlear Implant Quality of Life Profile (CIQOL-35)

    Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health.

    Time frame: Preimplantation to 12-months post-activation

  4. Health Utilities Index (HUI 2/3)

    Health Utilities Index (HUI 2/3) Global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health"

    Time frame: Preimplantation to 12 months post-activation

  5. Living with Cochlear Implants Questionnaire (LivCI)

    Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial \& Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management \& Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report.

    Time frame: Preimplantation to 12 months post-activation

  6. Patient Satisfaction Survey

    Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system.

    Time frame: 6 to 12 months post-activation

  7. Short Form (SF)-36 Health Survey

    SF-36 is scored for eight health domains, each scaled from 0 to 100, where a higher score indicates better health.

    Time frame: 8 to 10 months post-activation

  8. Time on air

    Hours of TICI System usage

    Time frame: Initial activation to 12 months post-activation

08

Study locations

8 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

Of 80 industry-sponsored interventional studies with no phase under Hearing Loss, Sensorineural, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 23. This study's planned 16 months is above that.

Counting every sponsor, half of 162 studies reached it within 22 months; a quarter within 6 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2025
First posted
Aug 24, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07139327
Lead sponsor
Cochlear
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Dec 1, 2025
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion